Dongwha Pharm and Animus Cure Jointly Research Innovative Sarcopenia Treatment Development

From the left, Yujunha, CEO of Dongwha Pharm, Kang Jongsun, CEO of Animus Cure, and Bae Gyuun, CEO.

[Asia Economy Reporter Lee Gwan-joo] Dongwha Pharm announced on the 2nd that it has signed a joint research agreement with AnimusCure, a muscle-specialized research and development company, to develop treatments for sarcopenia.

Through this agreement, the two companies will conduct joint research to derive and develop innovative candidate substances for synthetic new drug treatments for muscle diseases currently being researched by Dongwha Pharm.

Based on its capabilities in developing new drugs using low-molecular compounds, Dongwha Pharm will synthesize and derive candidate substances for sarcopenia treatment, while AnimusCure will conduct efficacy evaluations and mechanism studies. Patents for the research results will be jointly filed by both companies, and Dongwha Pharm will exclusively own the rights for productization and commercialization.

Yoo Jun-ha, CEO of Dongwha Pharm, said, “With aging, sarcopenia among the elderly is also expected to increase, but there is still no appropriate treatment, resulting in a high unmet medical need. Through this agreement, we expect to efficiently derive an innovative muscle disease treatment pipeline by leveraging the research capabilities of both companies.”

Meanwhile, AnimusCure is a muscle-specialized research and development company established in 2020 by Professor Kang Jong-soon of Sungkyunkwan University School of Medicine and Professor Bae Gyu-woon of Sookmyung Women’s University College of Pharmacy, who have long specialized in muscle growth and aging research.

This content was produced with the assistance of AI translation services.